Lanser Lukas, Fuchs Dietmar, Scharnagl Hubert, Grammer Tanja, Kleber Marcus E, März Winfried, Weiss Günter, Kurz Katharina
Department of Internal Medicine II, Innsbruck Medical University, Innsbruck, Austria.
Institute of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria.
Front Cardiovasc Med. 2021 Aug 12;8:666638. doi: 10.3389/fcvm.2021.666638. eCollection 2021.
Anemia is often found in patients with coronary artery disease (CAD) or acute coronary syndrome (ACS) and related to disease severity. Our study investigated the relationship between anemia, iron homeostasis and inflammation in CAD and examined their influence on the outcome of patients. Markers of immune activation (neopterin, interleukin [IL]-12, IL-6, high sensitive C-reactive protein (hsCRP), fibrinogen, serum amyloid A [SAA]) and iron metabolism (ferritin, transferrin saturation, hemoglobin) were determined in 2,082 patients (68.7 % men, median age 63 years) from the Ludwigshafen Risk and cardiovascular Health (LURIC) cohort. Patients were followed-up for a median of 9.81 years. 960 patients (46.1 %) presented with chronic CAD, 645 patients (31.0 %) had an ACS, and 477 patients (22.9 %) presented with no CAD in coronary angiography (CAG). Anemia ( = 357, 17.1 %) was associated with disease severity (reflected by more progressed stenosis in CAG, CCS, and NYHA classes, and a lower LV-EF), a higher cardio-cerebrovascular event rate and higher levels of inflammatory markers. Interestingly, anemia was only predictive for an adverse outcome in patients with elevated inflammatory markers. Accordingly, anemia of chronic disease (ACD) was associated with a higher cardio-cerebrovascular event-rate in the subsequent 2 years as compared to patients with other types of anemia or without anemia (14.3 vs. 6.1 vs. 4.0%, < 0.001). This study confirms that anemia and immune activation are strongly related to cardiovascular disease progression and an adverse outcome. Our data suggest that the association of anemia with disease severity and outcome might mainly be due to underlying inflammation.
贫血在冠状动脉疾病(CAD)或急性冠状动脉综合征(ACS)患者中较为常见,且与疾病严重程度相关。我们的研究调查了CAD患者贫血、铁稳态与炎症之间的关系,并探讨了它们对患者预后的影响。在路德维希港风险与心血管健康(LURIC)队列中的2082例患者(68.7%为男性,中位年龄63岁)中测定了免疫激活标志物(新蝶呤、白细胞介素[IL]-12、IL-6、高敏C反应蛋白(hsCRP)、纤维蛋白原、血清淀粉样蛋白A[SAA])和铁代谢标志物(铁蛋白、转铁蛋白饱和度、血红蛋白)。患者的中位随访时间为9.81年。960例患者(46.1%)表现为慢性CAD,645例患者(31.0%)发生ACS,477例患者(22.9%)在冠状动脉造影(CAG)中未发现CAD。贫血(n = 357,17.1%)与疾病严重程度相关(通过CAG中更严重的狭窄、加拿大心血管学会(CCS)分级和纽约心脏协会(NYHA)分级以及更低的左心室射血分数(LV-EF)反映)、更高的心脑血管事件发生率和更高水平的炎症标志物。有趣的是,贫血仅对炎症标志物升高的患者的不良预后具有预测性。因此,与其他类型贫血或无贫血的患者相比,慢性病贫血(ACD)患者在随后2年中心脑血管事件发生率更高(14.3%对6.1%对4.0%,P < 0.001)。本研究证实贫血和免疫激活与心血管疾病进展及不良预后密切相关。我们的数据表明,贫血与疾病严重程度及预后的关联可能主要归因于潜在的炎症。